Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin by Cohan, Reza Ahangari et al.
© 2011 Cohan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 1217–1227
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1217
OrIgINAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S19081
Design, modeling, expression, and chemoselective 
Pegylation of a new nanosize cysteine analog  
of erythropoietin
reza Ahangari Cohan1
Armin Madadkar-sobhani2,3
hossein Khanahmad1
Farzin roohvand4
Mohammad reza Aghasadeghi4
Mohammad hossein hedayati5
Zahra Barghi5
Mehdi shafiee Ardestani4
Davoud Nouri Inanlou1
Dariush Norouzian1
1research and Development 
Department, Production and 
research Complex, Pasteur Institute 
of Iran, Tehran, Iran; 2Department 
of Bioinformatics, Institute of 
Biochemistry and Biophysics, 
University of Tehran, Tehran, Iran; 
3Department of Life sciences, 
Barcelona supercomputing Center, 
Barcelona, spain; 4hepatitis and AIDs 
Department, Pasteur Institute of 
Iran, Tehran, Iran; 5Quality Control 
Department, Production and research 
Complex, Pasteur Institute of Iran, 
Tehran, Iran
Correspondence: Dariush Norouzian 
Pilot Biotechnology Department,  
Pasteur Institute of Iran,  
Tehran, Iran 
Tel +98 21 6646 5406 
Fax +98 21 6640 2771 
email dnsa@pasteur.ac.ir
Background: Recombinant human erythropoietin (rhEPO) is considered to be one of the most 
pivotal pharmaceutical drugs in the market because of its clinical application in the treatment 
of anemia-associated disorders worldwide. However, like other therapeutic proteins, it does 
not have suitable pharmacokinetic properties for it to be administrated at least two to three times 
per week. Chemoselective cysteine PEGylation, employing molecular dynamics and graphics 
in in silico studies, can be considered to overcome such a problem.
Methods: A special kind of EPO analog was elicited based on a literature review, homology 
modeling, molecular dynamic simulation, and factors affecting the PEGylation reaction. Then, 
cDNA of the selected analog was generated by site-directed mutagenesis and subsequently 
cloned into the expression vector. The construct was transfected to Chinese hamster ovary/
dhfr- cells, and highly expressed clones were selected via methotrexate amplification. 
Ion-immobilized affinity and size exclusion (SE) chromatography techniques were used to 
purify the expressed analog. Thereafter, chemoselective PEGylation was performed and a 
nanosize PEGylated EPO was obtained through dialysis. The in vitro biologic assay and in vivo 
pharmacokinetic parameters were studied. Finally, E31C analog Fourier transform infrared, 
analytical SE-high-performance liquid chromatography, zeta potential, and size before and 
after PEGylation were characterized.
Results: The findings indicate that a novel nanosize EPO31-PEG has a five-fold longer 
terminal half-life in rats with similar biologic activity compared with unmodified rhEPO 
in proliferation cell assay. The results also show that EPO31-PEG size and charge versus 
unmodified protein was increased in a nanospectrum, and this may be one criterion of EPO   
biologic potency enhancement.
Discussion: This kind of novel engineered nanosize PEGylated EPO has remarkable advantages 
over rhEPO.
Keywords: nanoPEGylated EPO, cysteine PEGylation, pharmacokinetic property
Introduction
Erythropoietin (EPO) is synthesized in the kidney and plays an important role in 
the production and differentiation of erythroid progenitors to mature erythrocytes 
in hypoxia conditions, which is a process called erythropoiesis.1 A defect in the 
production of EPO in the body leads to a decrease in red blood cells (anemia), which 
results from chronic kidney disease, chemotherapy, and azidothymidine treatment of 
HIV .2 The production of recombinant human EPO (rhEPO) is developed genetically 
by many biopharmaceutical industries, as it is widely used in anemia disorders. The 
available rhEPO is a highly glycosylated protein (40% of molecular weight) and 
comprises 165 amino acids with a ∼35 kDa molecular weight.3 Due to post-translational International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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modification, particularly in glycosylation pattern, and 
concerns about oncogenes in respect of human cell lines, it 
is expressed commercially in Chinese hamster ovary (CHO) 
and baby hamster kidney cells.4,5
Many scientists have studied the expression of EPO in 
systems such as Escherichia coli,6 Saccharomyces cervisiae,7 
and bacullovirus,2 but because of rapid clearance from the 
circulation due to differences in sialic acid content, expressed 
EPOs did not have efficient in vivo activity. Nevertheless, 
CHO-expressed rhEPO has a half-life of 4–13 hours. In order 
for it to have therapeutic effect, it should be administered 
two to three times per week, which, in addition to the high 
cost of treatment, means frequent intravenous administration 
for patients.2 Therefore, there has been growing interest in 
the development of long-acting products to be administered 
less often than existing products.
One of the approved approaches for the improvement 
of pharmacokinetic properties of biologic products is 
PEGylation. PEGylation can lead to an increase in size, 
drug solubility, and bioavailability, while decreasing dose 
frequency as well as immunogenicity.8,9 The prominent 
marketing of some PEGylated proteins in the last decades 
has shifted the focus to the marketing of other PEGylated 
proteins.10
Basic problems with the existing PEGylated proteins are 
inefficient conjugation yield, the formation of heterogeneous 
mixtures, and a decrease in biologic activity as a result of 
nonspecific PEGylation.11 For example, the only marketed 
PEGylated form of rhEPO, CERA®, was generated by 
conjugation of 30 kDa methoxy-PEG via amide bonds to 
the N-terminal or the amino groups of lys-52 or   lys-45.12,13 
These drawbacks can be successfully compensated by 
chemoselective cysteine PEGylation, which is a strong 
tool for improvement of pharmacokinetic properties of 
therapeutic proteins. However, the addition of free cysteine 
residue to protein is not simple and occurs commonly in 
cysteine PEGylation because of the rare existence of free 
cysteine residue in the proteins. Introduced cysteine residue 
must not change the three-dimensional (3D) structure or 
stability of protein.14 In addition, factors affecting PEGylation 
must also be considered because experimental analysis of all 
stable cysteine analogs is a very time-consuming and costly 
process. Therefore, rational selection of suitable sites for 
replacement with cysteine residue is a critical step for this 
method.11,14 It has already been shown that an increase or 
decrease in the protein nanosize or charge by PEGylation 
may significantly affect protein biologic properties, including 
half-life, potency, and stability.15,16
In the present study, a novel nanosize PEGylated rhEPO 
has been developed and evaluated based on a literature 
review, homology modeling, molecular dynamic (MD) 
simulations, factors affecting PEGylation, and biologic 
assays that have a bigger nanosize, more negative charge, 
and better pharmacokinetic properties with the same in vitro 
biologic potency compared with intact rhEPO.
Materials and methods
selection of a position for replacement 
by cysteine residue using an in silico 
approach
A literature review was performed for finding nonstructural 
and nonfunctional residues. 3D structures of cysteine analogs 
were generated by homology modeling using MODELLER 
version 9.5 and a crystal structure of EPO (PDB code: 1EER, 
chain A, 1.9 Å) as a template (http://www.salilab.org).17 For 
each cysteine analog or native EPO, 10,000 molecules were 
generated, and the molecule corresponding to the lowest value 
of probability density function was selected. The quality of 
models was checked using discrete optimized protein energy 
(DOPE) score profile18 and PROCHECK (http://www.
biochem.ucl.ac.uk).11 The stability of modeled analogs was 
examined by MD simulation using a GROMACS 3.3 package 
(http://www.gromacs.org) and Gromos96 force field.19 MD 
simulations were carried out at a constant temperature (300 K) 
and pressure (1 bar) for 5–15 ns. After calculating the average 
structures corresponding to the last 500–2000 ps of MD 
simulations, modeled cysteine analogs with a root mean square 
deviation (RMSD) of less than 4 Å from the initial structure 
were chosen for further analysis. Stable cysteine analogs 
were subjected to screening based on the RMSD from native 
EPO, surface area accessibility of engineered cysteine residues 
(cysteine-SAA), and pKa values of the thiol group. All-atom 
RMSDs between native EPO and the selected analogs were 
calculated by Qmol software (http://www.mbg.cornell.edu).20 
The pKa of thiol groups was determined by PROPKA 2.0 Web 
interface (http://propka.ki.ku.dk).21 Cysteine-SAA in the 
modeled analogs was computed by GETAREA server (http://
curie.utmb.edu).22 Cysteine analogs with SSA more than 50% 
were considered to be solvent exposed. Finally, one cysteine 
analog was selected for experimental analysis.
Construction of an expression vector 
containing an engineered cysteine analog
The cDNA of EPO was obtained by the reverse transcriptase-
polymerase chain reaction (RT-PCR) method from Hep G2 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Cell line (ATCC No. HB-8065, USA) and cloned into the 
pTZ57R/T using first cDNA synthesis and a T/A cloning 
kit, respectively (Fermentas, Vilnius, Lithuania). A His-
tag and kozak sequence were added to the C-terminal and 
N-terminal of EPO’s cDNA with a forward primer, 5′-ATT 
ATG GGG GTG CAC GAA TGT CCT G-3′, and a reverse 
primer, 5′-TCA ATG ATG ATG ATG ATG ATG GTC CCC 
TGT CCT GCA G-3′, respectively. Replacement of glutamic 
acid at position 31 with cysteine was performed by the site-
directed mutagenesis method using a forward primer 31, 
5′-GCT TGT CAC TGC AGC TTG AAT GAG AAT ATC 
AC-3′, and a reverse primer 31, 5′-CAT TCA AGC TGC 
AGT GAC AAG CAC AGC CCG TCG TG-3′. All PCRs 
were performed with Pfu DNA polymerase to avoid unex-
pected mutations (Fermentas). The mutated gene was cloned 
into the optiCHO vector (Topo T/A cloning kit, Invitrogen 
Inc, Carlsbad, CA). Finally, the accuracy of the construction 
was confirmed by restriction analysis and sequencing.
expression of the engineered cysteine 
analog in the ChO cell line
CHO/dhfr- (1.5 × 105) cells (ATCC No. CRL-9096, USA) 
were cultured in Iscove’s modified Dulbecco’s medium 
supplemented with 10% (v/v) fetal bovine serum (GIBCO, 
Invitrogen Inc), penicillin (100 units/mL), streptomycin 
(100 µg/mL), hypoxanthine (0.1 mM) (Sigma-Aldrich, 
Munich, Germany), thymidine (0.016 mM) (Sigma-Aldrich), 
and methotrexate (0.002 mM) (Sigma-Aldrich) in a 24-well 
microplate. The final construct was linearized by SspI 
(Fermentas) and transfected using a lipofectamin 2000 kit 
(GIBCO, Invitrogen, Inc). Transfected cells were selected 
in dialyzed α-MEM medium containing 10% dialyzed 
FBS without any nucleosides (GIBCO, Invitrogen Inc). 
The resulting clones were subjected to gene amplification 
using increasing doses of methotrexate (Sigma-Aldrich). 
High-expressing clones were selected by EPO ELISA 
kit (Roche Diagnostics GmbH, Mannheim, Germany). 
RT-PCR and sequencing were carried out to confirm the 
existence of replaced cysteine codons at the mRNA level, 
first using a cDNA synthesis kit either by oligo-dT, random 
hexamer, or specific primers (Fermentas). Finally, secre-
tion of cysteine analogs was analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
in a 12% resolving gel at 200 V for ∼50 minutes using the 
Mini-PROTEIN® Tetra Cell system (Bio-Rad Laboratories, 
Hercules, CA) and visualized by the Coomassie brilliant 
blue staining method.23 Electroblotting was performed using 
a Mini Trans-Blot® electrophoretic transfer cell (Bio-Rad 
Laboratories) to Whatman nitrocellulose membrane 
(Schleicher and Schuell, Riviera Beach, FL) for 1 hour. 
Membrane was blocked in 5% bovine serum albumin and 
0.1% Tween 20 in phosphate buffered saline (PBS) at 4°C 
overnight. The identification of expressed E31C analog was 
performed by employing the mouse monoclonal antibody 
against rhEPO (GeneTex Inc, Irvine, CA) and goat antimouse 
immunoglobulin G (HRP) (GeneTex Inc) as a primary and 
secondary antibody for 1 hour at room temperature. The 
band was developed using a DAB chromogenic substrate 
(Sigma-Aldrich).
Purification of the expressed  
cysteine analog
Cell culture supernatant was concentrated 10-fold using a 
Labscale TFF system (Millipore, Billerica, MA) equipped 
with a PXC010C50 cassette (Pellicon XL, Millipore). 
Simultaneously, buffer exchange was carried out three times 
with PBS. An ion immobilized affinity chromatography 
(IMAC) was applied for purification of the cysteine analog 
using 5 mL Histrap columns (GE Healthcare Inc, Princeton, 
NJ). The column was pre-equilibrated with 0.02 M sodium 
phosphate 0.5 M NaCl and 20 mM imidazole adjusted to 
pH 7.4. After sample loading and washing of columns with 
equilibration buffer, anchored cysteine analog was eluted with 
0.02 M sodium phosphate 0.5 M NaCl and 0.5 M imidazole 
(pH 7.4). An additional purification step was performed 
for elimination of imidazole and probable dimers by size 
exclusion chromatography (SEC) (HiLoad Superdex 75 prep 
grade, GE Healthcare). In this step, a solution containing 
50 mM sodium phosphate and 150 mM sodium chloride 
(pH 7) was used as an equilibration and elution buffer. All 
fractions containing cysteine analog were pooled and adjusted 
to the desired concentration using Microcon® centrifugal filter 
devices (Millipore). Finally, purified analog was aliquoted 
and stored at -80°C for further analysis.
Chemoselective Pegylation  
of engineered cysteine analog
PEGylation reaction was performed at room temperature and 
under nitrogen gas. Briefly, a 30-fold molar excess of TCEP 
(Tris [2-carboxyethyl] phosphine- HCl) (Sigma-Aldrich) and 
a 30-fold molar excess of 30 kDa mPEG-maleimide (SunBio 
Inc, Anyang City, South Korea) were added to a solution of 
E31C analog (250 µg/mL) in 50 mM Tris buffer pH 8.0 and 
incubated for 3 hours. Then, the PEGylation reaction was 
terminated by adding 10-fold Tris buffer (20 mM, pH 8.0). 
Finally, the reaction was dialyzed against PBS, concentrated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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using Microcon® centrifugal filter devices (Millipore), and 
stored at -80°C for further analysis.
Characterization, size, and zeta potential 
of PEGylated and unmodified cysteine 
analog
SE-high-performance liquid chromatography (HPLC) 
(Shodex PROTEIN KW-802.5 SEC column, Shodex, Japan) 
was employed for analysis of the protein modification using 
50 mM sodium phosphate containing 150 mM sodium 
chloride (pH 7) as an equilibration and elution buffer. 20 µL 
of each sample was injected separately and monitored at 
214 nm. Also, the spectral changes of the E31C analog were 
analyzed by Fourier transform infrared (FTIR) spectroscopy 
(Thermo-Nicolet, NEXUS 870, Waltham, MA) before 
and after the conjugation. Through changes in IR spectra, 
we were able to show the surface conjugation and clarify 
which group was involved in the conjugation process. In 
addition, EPO31-PEG and E31C analog (0.02 mg/mL) 
were checked for any changes in the size and zeta potential 
distribution by DLS technique (Malvern, Zetasizer Nano ZS, 
Worcestershire, UK).
Biological assays and pharmacokinetic 
studies
In vitro assays of all samples were carried out based on 
proliferation of UT-7 cells as follows. UT-7 cells (ACC 137; 
DMSZ, Braunschweig, Germany) were grown in α-MEM 
supplemented with 20% FBS, 40 mg/mL gentamycin, 2 mM 
glutamine, and 5 ng/mL GM-CSF (Sigma-Aldrich). Five 
thousands cells were seeded in each well of a 96-plate. Two-
fold serial dilutions of the protein samples and standard were 
prepared in assay media. One hundred μL of the diluted pro-
tein samples was added in triplicate to each well of a 96-well 
microplate. Ten thousand cells were washed and seeded in 
each well and incubated at 37°C in humidified 5% CO2 for 
3 days. PBS and 200 ng/mL rhEPO (R&D Systems, Min-
neapolis, MN) were added to the cultured cells as a negative 
and positive control, respectively. Proliferation of cells was 
measured by MTT assay, a technique based on the reduction 
of MTT to formazan by viable cells.24 Finally dose-response 
curves were drawn for rhEPO, E31C analog, and EPO31-
PEG. Animal experiments were performed with the approval 
of the Animal Ethics Committee of the Pasteur Institute of 
Iran. The five Sprague-Dawley rats (300 g ± 30 g weight) 
in each group received a single intravenous dose of 30 µg 
protein/kg.12 Blood samples were collected from the lateral 
tail vein at 15 minutes, 1 hour, 8 hours, 24 hours, 48 hours, 
96 hours, 120 hours, and 144 hours after the injection. The 
collected samples were centrifuged at 1500 g for 12 minutes, 
and separated plasma was analyzed using an EPO ELISA kit 
(Roche Diagnostics GmbH). The terminal half-life and the 
area under the curve were determined using linear regression 
of the last three plasma concentrations and a linear trapezoi-
dal method with extrapolation to infinity, respectively. Protein 
concentrations were determined using a Bradford dye binding 
assay. Statistical analysis of the data was performed using 
Student’s t-test and one-way multivariate analysis of variance 
to calculate the level of significance value (P-value). Values 
of P , 0.05 were considered statistically significant.
Results
selection of a position for replacement 
with cysteine residue using an in silico 
approach
From 165 residues in the EPO, 115 positions were excluded 
based on a literature review (Table 1). The 3D structures of 
selected analogs were generated successfully from related 
sequences using homology modeling because of high 
homology (above 95%) between the template and cysteine 
analogs. The quality of modeled analogs was verified by 
Ramachandran plot and DOPE score profile. Over 98% of 
residues in the generated models are located in regions based 
on ψ and ϕ angels, as shown in Figure 1A for E31C analog. 
DOPE score profile of cysteine analogs did not show any 
energy differences compared with the template, as depicted 
in Figure 1B for E31C analog. MD analysis was performed 
for all analogs in 5–15 ns, and RMSD versus time was plotted 
for the evaluation of model stability and average structure 
calculations (Figure 1C). Stable cysteine analogs during MD 
simulations (40 analogs) were subjected to screening based 
on the SAA of replaced cysteine residue (Table 2), and 13 
exposed cysteine analogs were selected. Then, pKa values 
Table 1 exclusion of residues involved in receptor binding or 
structural stability of erythropoietin, based on a literature review
Number of amino acids Exclusion criteria Reference
8–26, 55–83, 90–112, 138–161 essential for  
secretion
28
43–54 Conformational  
change
28
38–40, 24–26, 83–85 glycosylation site 3,43,44
29, 33, 7, 161 Disulfide bond 28,29,45
20, 44–47, 131, 140, 143, 147, 150 receptor binding  
site 1
32
8, 14, 97, 100, 103, 104 receptor binding  
site 2
32International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of the thiol group and whole RMSD versus native EPO were 
determined (Table 3). Finally, based on having maximum 
cysteine-SSA and pKa first and then the minimum RMSD 
from native EPO in the final average structure, the E31C 
analog was chosen for experimental analysis.
Construction, expression, and biologic 
evaluation of e31C analog
The natural cDNA of EPO was obtained by the RT-PCR 
method and T/A cloned into pTZ57R/T. The addition of 
His-tag, kozak sequence, and replacing of glutamic acid by 
cysteine codon were performed simultaneously by overlap 
extension PCR using respective primers (Figure 2). The 
mutated gene was cloned successfully into an optiCHO vec-
tor, and then the accuracy of the construct was confirmed by 
restriction analysis and sequencing (data not shown). The 
linearized construct was transfected into CHO/dhfr- cells, 
and expressing clones were obtained in selective mediums. 
The E31C-expressing clones were subjected to methotrexate 
amplification (Figure 3A), and a high-expressing clone was 
selected using the ELISA method. The existence of replaced 
cysteine codon in the mRNA was confirmed by RT-PCR 
and sequencing (data not shown). The identification of 
expressed cysteine analog was carried out using an anti-EPO 
antibody on nitrocellulose membrane (Figure 3C). The veri-
fied clone was cultured, and harvested supernatants were con-
centrated and immediately purified using IMAC and SE, as 
described in Materials and methods (Figure 3B). The biologic 
tests did not show any distinction in the activity of rhEPO, 
and the E31C analog EC50 (protein concentration achieving 
50% of the maximum effect) for E31C analog and rhEPO 
were obtained, 0.53 ± 0.03 and 0.52 ± 0.04, respectively 
(Figure 4A).
Characterization of Pegylated  
and unmodified analog
The purified E31C analog and the PEGylated form were 
monitored by injection of each sample to an analytical 
SE-HPLC. As revealed in the chromatogram, the peak 
PEGylated form was eluted from the column ∼6 minutes 
after the injection, which is earlier than the unmodified 
analog, as expected (Figure 5). The unmodified protein 
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Figure 1 Quality assessment of the modeled three-dimensional structure of the r31C analog as a sample. A) .98% of residues are in the allowed regions of the 
ramachandran plot. B) Discrete optimized protein energy (DOPE) score profile of modeled E31C analog and template. C) root mean square deviation (rMsD) plot for 
modeled E31C analog during molecular dynamic simulation. The fluctuations of the modeled structure reached plateau after ∼1500 ps of simulation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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peak appeared ∼20 minutes after the injection. Surprisingly, 
biologic activity of EPO31-PEG indicated no significant 
difference either by rhEPO or by E31C analog (Figure 4A). 
Also, in animal experiments, illustrated in Figure 4B, EPO31-
PEG showed a five-fold terminal half-life compared with 
the E31C analog. In the FTIR spectra of engineered analog,   
a peak appeared at 2414 cm-1 (Figure 6A), which endorsed 
the substitution of free cysteine, whereas it was not observed 
in the rhEPO spectrum (data not shown). After PEGylation 
of the engineered analog with 30 kDa PEG-maleimide, a 
peak at 2414 cm-1 was missed and a peak raised at 2486 cm-1 
(Figure 6B). This peak was related to C-H bound conjugated 
PEG polymer and confirmed that conjugation occurred in the 
free thiol group of replaced cysteine. The PEGylated analog 
showed an approximately two-fold increase in nanosize 
(from 3.1 nm ± 0.3 nm to 5.9 nm ± 0.2 nm) relative to the 
unmodified protein (Figure 7A). Zeta potential results also 
showed an increase in negative charge of PEGylated analog 
due to attachment of the PEG polymer (Figure 7B). Finally, 
animal studies showed that PEGylated analogs have a lower 
elimination rate than unmodified analogs, as well as other 
improved pharmacokinetic parameters (see Table 4).
Discussion
Covalent attachment of PEG to proteins via cysteine 
residue, known as cysteine PEGylation, is considered an 
extremely efficient approach to circumventing product 
heterogeneity and loss of biologic activity characteristic of 
amine-PEGylation.25 Several grants were allocated to Bolder 
BioTechnology Inc (www.bolderbio.com) by the National 
Institutes of Health for cysteine PEGylation of therapeutic 
proteins. This method has some limitations in practice. 
Functional or structural stability of cysteine analogs and 
factors affecting conjugation must be considered, because 
experimental analysis of all positions in the protein is a very 
time-consuming and costly process.14
Desjarlais and Zalevsky26 reported a computational 
method for rational cysteine PEGylation. The method 
determines the ratio of the ranges of motion of the PEG for 
protein alone versus protein complexed with its receptor. This 
ratio is related to activity when PEG is coupled at a specific 
site in the protein, but this method does not evaluate the 
effects of introduced free cysteine on the conformation and 
stability of the protein. Therefore, to the authors’ knowledge, 
there is no straightforward approach for rational site selection 
that comprises all aspects of cysteine PEGylation.
Our in silico approach consists of three steps. The first 
step is the selection of sites that do not involve protein 
function. This step can be carried out easily by a literature 
Table 3 All-atom root mean square deviation (rMsD) and pKa values of the thiol group for stable cysteine analogs that had   
solvent-exposed cysteine
Analog RMSD (Å) pKa SAA (%) Analog RMSD (Å) pKa SAA (%)
r4C 2.991 9.00 54.2 A125C 3.440 7.12 51.8
L5C 2.889 9.00 60.6 L130C 3.739 9.00 78.1
T27C 3.250 8.03 57.1 T134C 2.985 8.91 52.2
e31C 2.942 9.00 100.0 r162C 3.127 8.38 72.9
e89C 2.706 9.00 96.6 T163C 3.204 8.64 51.9
K116C 4.025 8.56 72.6 r166C 3.116 8.89 70.8
D123C 3.628 9.00 88.7
Abbreviation: sAA, surface area accessibility.
Table  2  stability  of  modeled  analogs  after  molecular  dynamic 
simulations and surface area accessibility (sAA) of replaced cysteine
Cysteine 
analog
Stability SAA  
(%)
Cysteine  
analog
Stability SAA   
(%)
A1C stable 48.8 e117C stable 6.1
P2C Unstable A118C stable 2.8
P3C stable 6.7 I119C stable 47.4
r4C stable 54.2 s120C Unstable
L5C stable 60.6 P121C stable 17.6
I6C stable 22.1 P122C stable 7.7
T27C stable 57.1 D123C stable 88.7
g28C Unstable A124C stable 0.7
A30C Unstable A125C stable 51.8
e31C stable 100.0 s126C stable 28.2
h32C stable 45.6 A127C stable 30.1
s34C Unstable A128C stable 0.0
L35C stable 0.0 P129C stable 3.7
N36C stable 48.1 L130C stable 78.1
e37C Unstable T132C stable 25.8
V41C stable 0.0 I133C stable 41.1
P42C stable 10.3 T134C stable 52.2
Q86C Unstable A135C Unstable
P87C Unstable 48.7 D136C Unstable
W88C stable 0.9 T137C stable 43.7
e89C stable 96.6 r162C stable 72.9
g113C stable 9.4 T163C stable 51.9
A114C stable 0.0 g164C stable 42.4
Q115C stable 46.8 D165C stable 9.0
K116C stable 72.6 r166C stable 70.8International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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review, because almost all marketed recombinant proteins 
have been well studied. In this way, exclusion of residues 
involved in functional or structural stability of EPO was 
carried out successfully by literature review because of 
known EPO receptor binding sites (see Table 1).
In the second step, structural stability of analogs due to 
cysteine substitution must be evaluated. For this purpose, 
3D structures of cysteine analogs must be subjected to MD 
simulation.27 As indicated in Table 3, the selected analog 
modeling and MD simulations revealed many possible sites 
(∼40 positions) in the EPO structure for cysteine residue 
replacement, which did not disturb EPO structure by RMSD 
measurement. These findings are consistent with previous 
studies that examined bioactivity of mutated EPOs by site-
directed mutagenesis.2,28,29
In the third step, PEGylation factors must be assessed on 
stable modeled analogs. Factors affecting protein PEGylation 
include SAA, inherent nucleophilicity, and pKa of residue. 
Other factors, such as time, temperature, pH, and protein/
PEG ratio, depend on the PEGylation method and must be 
determined empirically.30,31 In the present study, PEGylation 
factors related to the protein were analyzed on modeled stable 
analogs of EPO. The thiol group of introduced cysteine 
residue must be accessible for a successful attack on PEG 
molecules.30 Therefore, cysteine analogs with low thiol SAA 
must be excluded. Also, PEG attacks on the cysteine residue 
on the protein surface are dependent on the nucleophilicity 
of cysteine residue. PEG attacks will take place easier when 
the pH of PEGylation reaction is higher than the pKa of the 
thiol group. Therefore, cysteine residues have pKa values less 
than the pH of the PEGylation reaction and are preferred for 
cysteine PEGylation.25 In combination with factors affecting 
PEGylation, only 13 positions remained for the further 
evaluations. As listed in Table 3, the selected positions were 
located structurally in the N-terminal, C-terminal, and AB, 
BC, and CD loops of EPO that are not involved in stability 
or activity. Among the remaining analogs, the E31C and 
E89C analogs showed suitable criteria, including high SAA 
and low conformational change relative to the EPO.
Our in silico findings are in agreement with another study, 
by Desjarlais and Zalevsky,26 that measured the ratio of the 
ranges of PEG motion. It concluded that the best positions 
12 34 56
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Figure  2  replacement  of  glutamic  acid  codon  with  cysteine  codon  using  site-
directed mutagenesis. Lanes 1, 3, and 5: 100 bp markers (Fermentas, Lithuania); 
lane 2: first fragment of mutated cDNA containing kozak sequence and replaced 
cysteine codon (∼200 bp); lane 4: second fragment of mutated cDNA containing 
his-tag and replaced cysteine codon (∼400 bp); and lane 6: the complete cDNA of 
e31C analog (∼600 bp).
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Figure 3 A) Methotrexate amplification of E31C analog (lanes 2, 3, 4, 5, and 6), visualized by Coomassie brilliant blue staining method. B) sodium dodecyl sulfate 
polyacrylamide gel electrophoresis analysis of purified E31C analog (∼35 kDa) using immobilized affinity chromatography and size exclusion. C) Western blot analysis of e31C 
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in the EPO for conjugation either by 2 kDa or 10 kDa PEG 
are Glu31, Ser85, and Ala125, which have optimal predicted 
conjugation efficiencies, stability, and functional activity. 
Substitution of Ser85 with cysteine disturbs N-glycosylation 
at Asn83, which is essential for in vivo activity of EPO. 
Long et al2 also showed that S85C analog is glycosylated 
partially at position Asn83. The N85C analog was excluded 
in the first step of our approach. It must be noted that 
Desjarlais and Zalevsky26 performed their simulations on 
the 1EER, which does not contain any glycosyl chain, but 
Ser126 is glycosylated in expressed EPO. Therefore, spatial 
restriction of the glycosyl chain at position 126 may influence 
the coupling efficiency of the polymer negatively, but, as 
indicated in Table 3, the pKa value of the thiol group in 
Ala125 is lower than the other selected analogs, which may 
compensate for lower thiol accessibility. The T27C analog has 
a similar condition as A125. The previously reported T26C 
analog lacks glycosylation at position 24, which affects in 
vivo bioactivity due to a decrease in sialic acid content and 
leads to rapid clearance from circulation.2 Therefore, cysteine 
substitution at this position does not seem to be logical. Our 
data reveal that neighbor residue Thr27 is more suitable than 
Thr26 because cysteine substitution at this position does not 
affect N-glycosylation at position 24. As indicated in Table 3, 
the E89C analog has good criteria for cysteine PEGylation, 
high SAA and low RMSD, which is consistent with the previ-
ous study by Long et al.2 Even being PEGylated with a high-
molecular-weight (20 kDa) PEG-maleimide, the E89C analog 
shows the same activity.2 L130C and T134C analogs are not 
suitable for PEGylation with a high-molecular-weight PEG 
because of their proximity to the R131, which is involved 
in receptor binding site 1 of EPO. PEGylation at these posi-
tions with 30 kDa PEG can reduce receptor binding affinity 
of PEGylated forms.32 PEGylation of positions located in the 
N-terminal (R4 and L5) and C-terminal (R162, T163, and 
R166) in the EPO are not logical because of spatial restriction 
in interaction between EPO and its receptors. As shown by 
Long et al,2 the attachment of 20 kDa PEG at positions A1, 
P3, and T163 decreases receptor binding affinity. In addition, 
it has been reported that terminal arginine of EPO is deleted 
from the CHO-expressed rhEPO. Therefore, remaining 
replaced cysteine at this position must be proved.33 K116C 
and D123C analogs show higher RMSD than other analogs, 
but both analogs have reasonable cysteine accessibility with 
closer pKa value. As reported, PEGylation at neighbor posi-
tion Q115 with a 20 kDa PEG-maleimide did not change 
receptor binding affinity.2
Based on the in silico studies, E31C and A118C analogs 
were chosen as PEGylation-positive and -negative models. 
Further verification was obtained when E31C and A118C 
analogs showed the same biologic activity, which further 
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proves that no structural or functional changes occurred (data 
not shown). The A118C analog showed a low PEGylation 
yield in the same conditions, as expected, because of low 
cysteine accessibility (see Table 3). In the case of the E31C 
analog, FTIR spectra confirmed both the existence of replaced 
cysteine analog and chemoselective PEGylation. The data 
also showed an increase in nanosize of EPO and an increase 
in half-life. Extended terminal half-life due to attachment 
of 30 kDa PEG is in agreement with findings from previous 
studies.12,34 The attachment of a 30 kDa PEG to the E31C ana-
log results in a five-fold increase in half-life, as reported by 
Agoram et al.12 It has been shown that PEGylation influences 
protein clearance and plays a crucial role in their elimination 
from the circulation.6 A 10-fold decrease in clearance of 
PEGylated E31C analog with 30 kDa PEG is comparable with 
another study in which a 30 kDa PEG attached to the NM385 
variant.12 In addition, it is reported that PEGylated proteins’ 
hydrodynamic volumes markedly increased as well.35 The 
present data propound two additional important criteria for 
nanoEPO half-life or biologic activity enhancement obser-
vations: i) increasing the size by PEGylation, as indicated 
in Figure 7A; and ii) the PEGylation was also found to be 
helpful in making the protein charge more negative rather 
than the intact EPO as well. On the other hand, an increase in 
EPO size (from 3 nm to 6 nm) or a negative charge resulted 
in a significant increase in biologic characteristics of new 
nanosize EPO. With this in mind, it has also been shown that 
the increase or decrease in the protein nanosize or charge by 
PEGylation may significantly affect protein biologic proper-
ties, including half-life, potency, and stability.15,16
Previous investigations have elucidated that longer-
acting products can be created by amine-reactive PEG 
conjugation.36–40 However, as discussed, the PEGylated 
products consist of multiple PEGylated forms, and varying 
biologic activities have usually reduced activity due to 
the conjugation extent of the protein. Many studies have 
been carried out on PEG conjugation of EPO, but the only 
marketed form is CERA®, which is attained by conjugation 
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of the PEG chain at the N-terminus and lysine residues 
predominantly at positions 45 or 52.12,13,41 TGase-mediated 
PEGylation, provided by Centocor, allows the attaching 
of one to three PEGs to the protein, but the identity of the 
modified residue could not be ascertained completely.42 
Therefore, the major problem associated with PEGylation 
is due to nonselective conjugation of protein, which leads to 
heterogeneity or a significant decrease in receptor affinity. 
Our findings show that when a high-molecular-weight PEG 
has been conjugated to a protein chemoselectively, then the 
aforementioned problem does not arise.16 As a result, our 
proposed in silico approach could be used as a promising 
methodology for rational PEGylation to remove all incon-
sistencies encountered.
Conclusion
The nanosize PEGylated E31C-EPO developed in this study 
shows better pharmacokinetic properties than rhEPO in rats, 
and further studies will be performed to prove its reliability 
in the management of anemia. Our results prove that using 
molecular modeling and MD simulations in rational site 
selection of cysteine-specific PEGylation is an emerging 
strategy in developing long-acting molecules. It is possible 
to use a similar approach to create long-acting forms of 
other recombinant proteins. Knowledge of factors affecting 
PEGylation in combination with computational techniques 
enable us to PEGylate proteins through cysteine residue 
rationally, without any of the problems that are common 
in other methods dealing with attaching a high-molecular-
weight polymer to a protein.
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